ArticleFrontiers in medicine2026
Hospital-based micro-elimination of hepatitis C virus: improving timely case identification and linkage to care in a tertiary hospital.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite the availability of highly effective direct-acting antivirals (DAAs), gaps in the hepatitis C virus (HCV) care cascade remain major barriers to elimination. Hospital-based micro-elimination strategies may help improve timely diagnosis and linkage to care. Methods: We retrospectively analyzed all patients who underwent anti-HCV antibody testing at Yuncheng Central Hospital between August 2021 and August 2024. Hospital-wide measures-including physician training, interdepartmental collaboration, and laboratory alert prompts for anti-HCV positive results-were implemented to improve referral and treatment. The cascade of care from screening to treatment outcomes was evaluated. Results: A total of 276,568 patients were screened for anti-HCV antibodies, identifying 4,011 seropositive individuals. Among them, 2,958 patients completed confirmatory HCV RNA testing, leading to the identification of 788 active infections. Among viremic patients, 423 (53.7%) initiated DAA therapy, all of whom completed treatment, with 418 (98.8%) achieving sustained virologic response at 12 weeks. Conclusion: Hospital-based micro-elimination strategies may help strengthen the HCV care cascade by enhancing confirmatory testing and linkage to treatment. Strengthening interdisciplinary collaboration and referral systems in tertiary hospitals may accelerate progress toward HCV elimination, particularly in high-prevalence regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.